[go: up one dir, main page]

IS4664A - Ný peptíð-ópíóíð - Google Patents

Ný peptíð-ópíóíð

Info

Publication number
IS4664A
IS4664A IS4664A IS4664A IS4664A IS 4664 A IS4664 A IS 4664A IS 4664 A IS4664 A IS 4664A IS 4664 A IS4664 A IS 4664A IS 4664 A IS4664 A IS 4664A
Authority
IS
Iceland
Prior art keywords
new peptide
peptide opioid
opioid
new
peptide
Prior art date
Application number
IS4664A
Other languages
English (en)
Inventor
Wang Wuyi
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS4664A publication Critical patent/IS4664A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1027Tetrapeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS4664A 1995-08-18 1998-02-04 Ný peptíð-ópíóíð IS4664A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides
PCT/SE1996/001011 WO1997007130A1 (en) 1995-08-18 1996-08-14 Novel opioid peptides

Publications (1)

Publication Number Publication Date
IS4664A true IS4664A (is) 1998-02-04

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4664A IS4664A (is) 1995-08-18 1998-02-04 Ný peptíð-ópíóíð

Country Status (27)

Country Link
US (1) US6337319B1 (is)
EP (1) EP0845003B1 (is)
JP (1) JPH11512086A (is)
KR (1) KR19990037677A (is)
CN (1) CN1200127A (is)
AR (1) AR003475A1 (is)
AT (1) ATE210148T1 (is)
AU (1) AU711862B2 (is)
BR (1) BR9610248A (is)
CA (1) CA2229797A1 (is)
CZ (1) CZ287299B6 (is)
DE (1) DE69617699T2 (is)
DK (1) DK0845003T3 (is)
EE (1) EE9800048A (is)
ES (1) ES2171224T3 (is)
HU (1) HUP9901209A3 (is)
IL (1) IL123258A (is)
IS (1) IS4664A (is)
NO (1) NO980592D0 (is)
NZ (1) NZ315809A (is)
PL (1) PL325113A1 (is)
RU (1) RU2165432C2 (is)
SE (1) SE9503924D0 (is)
SK (1) SK282469B6 (is)
TR (1) TR199800258T1 (is)
TW (1) TW424095B (is)
WO (1) WO1997007130A1 (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2001013938A1 (fr) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
US7498297B2 (en) 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006132925A2 (en) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (en) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
JP5244810B2 (ja) 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) * 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
AU672077B2 (en) * 1992-11-12 1996-09-19 Biomeasure, Inc. Opioid peptides
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
IS4261A (is) * 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
IL123258A (en) 2003-03-12
US6337319B1 (en) 2002-01-08
EP0845003B1 (en) 2001-12-05
AU711862B2 (en) 1999-10-21
DE69617699T2 (de) 2003-08-07
CN1200127A (zh) 1998-11-25
SE9503924D0 (sv) 1995-11-07
EP0845003A1 (en) 1998-06-03
KR19990037677A (ko) 1999-05-25
AU6760096A (en) 1997-03-12
NZ315809A (en) 1999-05-28
RU2165432C2 (ru) 2001-04-20
HUP9901209A2 (hu) 1999-08-30
DE69617699D1 (de) 2002-01-17
BR9610248A (pt) 1999-07-06
WO1997007130A1 (en) 1997-02-27
IL123258A0 (en) 1998-09-24
AR003475A1 (es) 1998-08-05
TR199800258T1 (xx) 1998-05-21
TW424095B (en) 2001-03-01
ATE210148T1 (de) 2001-12-15
CZ287299B6 (en) 2000-10-11
EE9800048A (et) 1998-08-17
NO980592L (no) 1998-02-11
SK282469B6 (sk) 2002-02-05
DK0845003T3 (da) 2002-07-15
ES2171224T3 (es) 2002-09-01
HUP9901209A3 (en) 2000-12-28
NO980592D0 (no) 1998-02-11
PL325113A1 (en) 1998-07-06
SK20398A3 (en) 1998-12-02
CZ40198A3 (cs) 1998-08-12
CA2229797A1 (en) 1997-02-27
JPH11512086A (ja) 1999-10-19

Similar Documents

Publication Publication Date Title
IS4664A (is) Ný peptíð-ópíóíð
EP0853483A4 (en) NEW PEPTIDES
PT805813E (pt) Antagonistas de vasopressina triciclicos
FI965225A7 (fi) Uusia peptidejä
DE69620006D1 (de) Sequenzierverfahren
DK0739831T3 (da) Transportør
DK0753474T3 (da) Transportør
FI961350A7 (fi) Hapteenimerkityt peptidit
NO985680D0 (no) Peptidderivater
IS4115A (is) Ný peptíð
NO983849D0 (no) Peptidderivater
BR9508433A (pt) Peptídeos
BR9609671A (pt) Amino uracilas substituídas
FI964363L (fi) Peptidejä
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
FI963568A7 (fi) Peptidijohdannaisia
NO981051D0 (no) Peptidderivater
FI965116L (fi) Uusia opioidipeptidiantagonisteja
FR2732345B1 (fr) Peptide antibacterien
IL113441A0 (en) Opioid peptide analoog
BR1100812A (pt) Peptìdeo
SE9504467D0 (sv) Peptide
KR970041607U (ko) 자동차의 시동장치
DK1017798T3 (da) Lunasinpeptider